The Latest Breaking News from GSK

  GlaxoSmithKline (NYSE:GSK) reported its Q1 earnings results on Wednesday, April 27, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

GlaxoSmithKline (NYSE:GSK) is set to give its latest quarterly earnings report on Wednesday, 2022-04-27. Here's what investors need to know before the announcement. Analysts estimate that GlaxoSmithKline will report an earnings per share (EPS) of $0.76.

Here's a roundup of top developments in the biotech space over the last 24 hours.

Sierra Oncology Inc (NASDAQ: SRRA) shares are trading significantly higher Wednesday after the company announced it will be acquired by GlaxoSmithKline PLC (NYSE: GSK) for $55 per share in cash, representing an a

Deal is in step with GSK’s strategy of building a strong portfolio of new specialty medicines and vaccines

GlaxoSmithKline plc (NYSE:GSK) has agreed to acquire Sierra Oncology Inc (NASDAQ:SRRA) for $55 per share in cash, representing an approximate total equity value of $1.9 billion (£1.5 billion). Sierra's momelotinib complements GSK's Blenrep (belantamab mafodotin), building on GSK's commercial and medical expertise in hematology.  If momelotinib is approved, GSK expects momelotinib will contribute to GSK's growing…

Germany has signed a contract with CureVac BV (NASDAQ:CVAC) and its partner GlaxoSmithKline plc (NYSE:GSK) for domestically produced mRNA vaccines to bolster supplies for pandemic preparedness. The five-year contract allows for the production of up to 80 million doses at short notice until 2029, CureVac said, adding that those doses could be for the remainder of…

Money includes a £2.5m Innovate UK grant to fund human clinical trials of its technology

The U.S. health regulator said GlaxoSmithKline Plc (NYSE:GSK) and Vir Biotechnology Inc's (NASDAQ:VIR) antibody therapy was no longer authorized as a COVID-19 treatment. The decision was made as the CDC now estimates that the proportion of Covid-19 cases caused by BA.2 is above 50% nationwide. "Sotrovimab is no longer authorized to treat COVID-19 in any…

As governments prepare to live with COVID-19, some are questioning how much to rely on drugmakers to adapt vaccines to ward off future virus variants amid signs of tension between companies and regulators over the best approach, according to several sources familiar with the matter.

CureVac N.V. (NASDAQ:CVAC) dosed the first participant in a Phase 1 study of COVID-19 second-generation mRNA vaccine candidate, CV2CoV, developed with GlaxoSmithKline plc (NYSE:GSK).  The clinical trial is expected to provide valuable data to evaluate further the performance of CureVac’s second-generation mRNA backbone, which has the potential to be applied broadly in future vaccines against…